[First issue] Tekoro Bio, a leader in the research and development of innovative skin drugs for external use, completes tens of millions of yuan in A round of financing

Sun Jigang, partner of Haisong Medical Ventures, said, “We are very pleased to have the opportunity to participate in this round of financing of Tekoro Bio.

Lead Capital Partner Chen Rui said: "In recent years, we are very pleased to see more and more scientists and entrepreneurs studying in the United States bringing innovation and experience back to China.

Tekoro is an innovative small molecule drug research and development enterprise focusing on the research and development of new dermatological drugs.

The core new drug R&D team of Tekoro Biosciences includes Dr.

Tekoro Biological Research and Development Team (from left to right: Dr.

Dr.

Dr.
Wenkui Fang is the company’s vice president of new drug development medicinal chemistry.
He completed his master's study and research at Nankai University, then went to the University of Michigan to study for a doctorate in the Department of Organic Chemistry, and then completed postdoctoral research at the University of Pennsylvania.
Dr.
Fang has been engaged in the research and development of new drugs for 15 years in the internationally renowned skin drug research and development company Allergan.
The disease field involves skin immune diseases, CNS and other diseases.
Few people can match the experience in the design and medicinalization of external drugs for skin diseases.
After leaving Allergan, Dr.
Fang successively served as the vice president of pharmaceutical companies such as Baoluo, Xuanzhu, Nivien, and was fully responsible for the research and development of innovative drugs.
Up to now, Dr.
Fang has published dozens of academic papers in internationally renowned academic journals, participated in inventions in drug R&D companies and holds more than 70 small molecule drug invention patents.

In the company's entire talent system structure, Tekoro Biotech has gathered excellent talent resources at home and abroad.
The company not only has a strong global team of scientists and consultants deeply involved in the development and project implementation of the company’s products, but most of its shareholders are also the founders, CEOs and other senior managers of pharmaceutical companies.
This makes Tecorro possess a wealth of innovative drug R&D and industry Experience and resource reserves.

About CDH VGC (Innovation and Growth Fund)

CDH Investment was established in 2002 and is one of the most influential alternative asset management institutions in China.
As of 2020, the scale of funds under management exceeds RMB 160 billion.
CDH Investments has six business segments: private equity investment, innovation and growth, securities investment, real estate investment, mezzanine investment, and wealth management.
CDH VGC (Innovation and Growth Fund) focuses on investment in healthcare, TMT and innovative growth opportunities with Chinese characteristics.
CDH Innovation and Growth Fund is managed by a professional investment team with rich experience and distinctive characteristics, committed to promoting the innovation and development of outstanding companies in the growth period.
Based on CDH Investment’s outstanding investment performance in the fields of healthcare and growth, and CDH’s investment focus in the TMT field, CDH Innovation and Growth Fund has established its own unique investment strategy and platform advantages, and relying on its investment team Abundant investment experience, professional judgment and operation management experience have comprehensively enhanced the value of the invested enterprise.

About Haisong Medical Ventures

，、。，，，，，，、。：、、、。、，

，。，，。